GSK (GSK) and Bellus Health (BLU) announced GSK has completed the acquisition of Bellus. Following the anticipated regulatory approval and launch of camlipixant, the acquisition is expected to be accretive to adjusted earnings from 2027 and has the potential to deliver “significant” sales through 2031 and beyond, the companies said in a statement.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on GSK:
- GSK receives FDA Fast Track designation for investigational gonorrhea vaccine
- GSK Pharma call volume above normal and directionally bullish
- GSK Rises after Reaching Settlement of Zantac Litigation
- GSK settling first Zantac bellwether case removes near-term risk, says BofA
- GSK announces legal settlement with James Goetz in Zantac case
